Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Total Non-Current Liabilities (2020 - 2025)

Bolt Biotherapeutics' Total Non-Current Liabilities history spans 6 years, with the latest figure at $32.8 million for Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 12.02% year-over-year to $32.8 million; the TTM value through Sep 2025 reached $32.8 million, down 12.02%, while the annual FY2024 figure was $42.4 million, 9.71% down from the prior year.
  • Total Non-Current Liabilities for Q3 2025 was $32.8 million at Bolt Biotherapeutics, down from $36.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $58.4 million in Q3 2021 and bottomed at $21.1 million in Q1 2021.
  • The 5-year median for Total Non-Current Liabilities is $47.1 million (2023), against an average of $45.4 million.
  • The largest annual shift saw Total Non-Current Liabilities surged 157.24% in 2022 before it fell 21.03% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $57.4 million in 2021, then decreased by 1.97% to $56.3 million in 2022, then fell by 16.46% to $47.0 million in 2023, then dropped by 9.71% to $42.4 million in 2024, then dropped by 22.66% to $32.8 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Total Non-Current Liabilities are $32.8 million (Q3 2025), $36.5 million (Q2 2025), and $38.9 million (Q1 2025).